<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004436</url>
  </required_header>
  <id_info>
    <org_study_id>199/13399</org_study_id>
    <secondary_id>CH-B-FDR000967</secondary_id>
    <nct_id>NCT00004436</nct_id>
  </id_info>
  <brief_title>Randomized Study of Hormonal Regulation of Infantile Hemangioma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the clinical efficacy of leuprolide, a gonadotropin-releasing hormone&#xD;
      agonist (GnRHa), in treating infants with vision-endangering or large, disfiguring&#xD;
      hemangiomas.&#xD;
&#xD;
      II. Assess the impact of GnRHa on growth and development during infancy. III. Assess the&#xD;
      safety of GnHRa in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, placebo-controlled study. Patients are stratified&#xD;
      according to gender and by position of the lesion (periorbital vs nonperiorbital).&#xD;
&#xD;
      All patients receive oral prednisone daily for 3 weeks. Patients are then randomized to&#xD;
      receive either placebo or leuprolide IM every 3 weeks, while continuing oral prednisone.&#xD;
      Tumors are assessed at 1, 3, and 6 weeks. If the tumor is not responding, the leuprolide will&#xD;
      be administered every 2 weeks. Tumors are reassessed at 3 and 6 months, at which point the&#xD;
      treatment is stopped. Responding patients are observed every 3 weeks for 3 months. If the&#xD;
      tumor begins to grow again, leuprolide may be administered for another 3 months. Patients&#xD;
      whose tumors grow rapidly during treatment may crossover to the alternate therapy, repeat the&#xD;
      leuprolide or prednisone therapy, or undergo surgical excision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1993</start_date>
  <completion_date>June 2000</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Hemangioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Presence of hemangioma meeting at least one of the following criteria:&#xD;
             Vision-threatening because of induced astigmatism or occlusion of the visual axis or&#xD;
             proptosis Severe anatomic distortion compromising function of an organ or creating an&#xD;
             unacceptable cosmetic outcome Other complications, e.g., Kasabach-Merritt consumptive&#xD;
             coagulopathy, high-output heart failure, etc.&#xD;
&#xD;
          -  No lesions that are clearly regressing before therapy&#xD;
&#xD;
          -  No vascular malformations other than juvenile hemangiomas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lois Hodgson Smith</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <verification_date>August 2000</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>hemangioma</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

